Drugging the Cancers Addicted to DNA Repair

Journal of the National Cancer Institute
109,
DOI: 10.1093/jnci/djx059

Citation Report

#	Article	IF	Citations
1	The evolving role of DNA inter-strand crosslinks in chemotherapy. Current Opinion in Pharmacology, 2018, 41, 20-26.	3.5	41
2	The Radiobiology of Proton Therapy: Challenges and Opportunities Around Relative Biological Effectiveness. Clinical Oncology, 2018, 30, 285-292.	1.4	56
3	A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. Clinical Cancer Research, 2018, 24, 2044-2049.	7.0	56
4	Targeting DNA repair: the genome as a potential biomarker. Journal of Pathology, 2018, 244, 586-597.	4.5	41
5	Advances in therapeutic targeting of the DNA damage response in cancer. DNA Repair, 2018, 66-67, 24-29.	2.8	46
6	A lncRNA GUARDINg genome integrity. Nature Cell Biology, 2018, 20, 371-372.	10.3	2
7	ADP-Ribosylation, a Multifaceted Posttranslational Modification Involved in the Control of Cell Physiology in Health and Disease. Chemical Reviews, 2018, 118, 1092-1136.	47.7	186
8	Carcinogenesis: Role of Reactive Oxygen and Nitrogen Species. , 2018, , 296-296.		0
9	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers, 2018, 10, 487.	3.7	154
10	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. Clinical Cancer Research, 2018, 24, 4887-4899.	7.0	74
11	T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system. Scientific Reports, 2018, 8, 9966.	3.3	17
12	Nucleotide Excision Repair Factor XPC Ameliorates Prognosis by Increasing the Susceptibility of Human Colorectal Cancer to Chemotherapy and Ionizing Radiation. Frontiers in Oncology, 2018, 8, 290.	2.8	18
13	The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. Cancer Biology and Therapy, 2018, 19, 786-796.	3.4	23
14	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Reports, 2018, 23, 3127-3136.	6.4	68
15	Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer. Molecular Genetics & Genomic Medicine, 2019, 7, e810.	1.2	7
16	Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma. Applied Microbiology and Biotechnology, 2019, 103, 9557-9568.	3.6	8
17	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. Cancers, 2019, 11, 1373.	3.7	13
18	Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. Expert Review of Anticancer Therapy, 2019, 19, 589-601.	2.4	8

#	Article	IF	Citations
19	Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. Biochemical Pharmacology, 2019, 164, 273-282.	4.4	29
20	Identification of Novel Interaction Partners of Ets-1: Focus on DNA Repair. Genes, 2019, 10, 206.	2.4	1
21	DNA Repair Gene Expression Adjusted by the PCNA Metagene Predicts Survival in Multiple Cancers. Cancers, 2019, 11, 501.	3.7	4
22	Small Molecule Docking of DNA Repair Proteins Associated with Cancer Survival Following PCNA Metagene Adjustment: A Potential Novel Class of Repair Inhibitors. Molecules, 2019, 24, 645.	3.8	7
23	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. Expert Review of Precision Medicine and Drug Development, 2019, 4, 11-25.	0.7	1
24	DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma. EBioMedicine, 2019, 41, 185-199.	6.1	77
25	Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response. Genes, 2019, 10, 25.	2.4	111
26	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. Leukemia and Lymphoma, 2019, 60, 1098-1101.	1.3	12
27	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. European Urology, 2020, 77, 144-155.	1.9	46
28	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia, 2020, 34, 234-244.	7.2	80
29	Epigenetic based synthetic lethal strategies in human cancers. Biomarker Research, 2020, 8, 44.	6.8	19
30	Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. Drug Resistance Updates, 2020, 53, 100720.	14.4	107
31	ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells. Heliyon, 2020, 6, e05097.	3.2	4
32	The SWI/SNF ATPase BRG1 stimulates DNA end resection and homologous recombination by reducing nucleosome density at DNA double strand breaks and by promoting the recruitment of the CtIP nuclease. Cell Cycle, 2020, 19, 3096-3114.	2.6	18
33	UBC13-Mediated Ubiquitin Signaling Promotes Removal of Blocking Adducts from DNA Double-Strand Breaks. IScience, 2020, 23, 101027.	4.1	17
34	Distinct roles of structure-specific endonucleases EEPD1 and Metnase in replication stress responses. NAR Cancer, 2020, 2, zcaa008.	3.1	11
35	DNA Damage: From Threat to Treatment. Cells, 2020, 9, 1665.	4.1	99
36	Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining. Cell Reports, 2020, 32, 108068.	6.4	29

#	Article	IF	Citations
37	DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns. Frontiers in Pediatrics, 2020, 8, 570084.	1.9	42
38	DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. Cancers, 2020, 12, 2098.	3.7	57
39	Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592095835.	3.2	27
40	Development and validation of a DNA repair gene signature for prognosis prediction in Colon Cancer. Journal of Cancer, 2020, 11, 5918-5928.	2.5	9
41	Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach. International Journal of Molecular Sciences, 2020, 21, 6684.	4.1	24
42	DNA Repair Biosensor-Identified DNA Damage Activities of Endophyte Extracts from Garcinia cowa. Biomolecules, 2020, 10, 1680.	4.0	0
43	Targeting DNA Damage Response in Prostate and Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 8273.	4.1	50
44	Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia. Medicinal Chemistry Research, 2020, 29, 962-978.	2.4	4
45	Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers. Frontiers in Oncology, 2020, 10, 670.	2.8	13
46	Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin. Frontiers in Pharmacology, 2020, 11, 186.	3.5	37
47	Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells. Oncogene, 2020, 39, 2905-2920.	5.9	37
48	Role of Rad51 and DNA repair in cancer: A molecular perspective. , 2020, 208, 107492.		64
49	Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy. Genes, 2020, 11, 99.	2.4	118
50	The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis. Scientific Reports, 2020, 10, 6920.	3.3	5
51	Dietary riboflavin deficiency induces ariboflavinosis and esophageal epithelial atrophy in association with modification of gut microbiota in rats. European Journal of Nutrition, 2021, 60, 807-820.	3.9	19
52	Reserpine inhibits DNA repair, cell proliferation, invasion and induces apoptosis in oral carcinogenesis via modulation of TGF-Î² signaling. Life Sciences, 2021, 264, 118730.	4.3	11
53	Human CtIP: A â€˜double agentâ€™ in DNA repair and tumorigenesis. Seminars in Cell and Developmental Biology, 2021, 113, 47-56.	5.0	25
54	The role of DNA damage and repair in liver cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188493.	7.4	23

#	Article	IF	Citations
55	The rediscovery of platinum-based cancer therapy. Nature Reviews Cancer, 2021, 21, 37-50.	28.4	452
56	Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy. , 2021, 4, 244-263.		14
58	Targeting proteinâ€"protein interactions in the DNA damage response pathways for cancer chemotherapy. RSC Chemical Biology, 2021, 2, 1167-1195.	4.1	14
59	Single-arm, open label prospective trial to assess prediction of the role ofÂERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. ESMO Open, 2021, 6, 100034.	4.5	0
60	The Role of Nucleotide Excision Repair in Cisplatin-Induced Peripheral Neuropathy: Mechanism, Prevention, and Treatment. International Journal of Molecular Sciences, 2021, 22, 1975.	4.1	10
61	EPHA2 Interacts with DNA-PKcs in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells. Cancers, 2021, 13, 1010.	3.7	8
62	RRM2B Is Frequently Amplified Across Multiple Tumor Types: Implications for DNA Repair, Cellular Survival, and Cancer Therapy. Frontiers in Genetics, 2021, 12, 628758.	2.3	9
63	Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation. Viruses, 2021, 13, 757.	3.3	16
64	PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation. Genes, 2021, 12, 849.	2.4	10
65	The Effects of Localized Heat on the Hallmarks of Cancer. Advanced Therapeutics, 2021, 4, 2000267.	3.2	19
66	Selective Inhibition of DNA Polymerase Î² by a Covalent Inhibitor. Journal of the American Chemical Society, 2021, 143, 8099-8107.	13.7	8
67	Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs. Oncology and Therapy, 2021, 9, 541-556.	2.6	11
68	Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. Cancers, 2021, 13, 3130.	3.7	13
69	Activation of the DDR Pathway Leads to the Down-Regulation of the TGFÎ² Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma. Frontiers in Immunology, 2021, 12, 634741.	4.8	20
70	Suppression of DNA Polymerase Î² Activity Is Synthetically Lethal in BRCA1-Deficient Cells. ACS Chemical Biology, 2021, 16, 1339-1343.	3.4	2
71	The Prognostic Value of the DNA Repair Gene Signature in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11, 710694.	2.8	2
72	Roles of homologous recombination in response to ionizing radiation-induced DNA damage. International Journal of Radiation Biology, 2023, 99, 903-914.	1.8	9
73	Protein Domain Specific Covalent Inhibition of Human DNA Polymerase Î². ChemBioChem, 2021, 22, 2619-2623.	2.6	1

#	Article	IF	Citations
74	Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics. Frontiers in Genetics, 2021, 12, 721873.	2.3	4
75	Targeted Therapy as a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: A Literature Review. Frontiers in Oncology, 2021, 11, 730412.	2.8	6
76	Cinobufagin-induced DNA damage response activates G2/M checkpoint and apoptosis to cause selective cytotoxicity in cancer cells. Cancer Cell International, 2021, 21, 446.	4.1	8
77	The Safe Path at the Fork: Ensuring Replication-Associated DNA Double-Strand Breaks are Repaired by Homologous Recombination. Frontiers in Genetics, 2021, 12, 748033.	2.3	21
78	Cell cycle control and DNA-damage signaling in mammals. , 2021, , 237-255.		0
79	SLX4â€"XPF mediates DNA damage responses to replication stress induced by DNAâ€"protein interactions. Journal of Cell Biology, 2021, 220, .	5.2	12
80	PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma. Oncotarget, 2018, 9, 23923-23943.	1.8	9
81	DNA Double Strand Break Repair - Related Synthetic Lethality. Current Medicinal Chemistry, 2019, 26, 1446-1482.	2.4	9
82	Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy. Current Topics in Medicinal Chemistry, 2019, 19, 730-740.	2.1	24
83	Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. ELife, 2019, 8, .	6.0	80
84	A signature of tumor DNA repair genes associated with the prognosis of surgically-resected lung adenocarcinoma. PeerJ, 2020, 8, e10418.	2.0	6
85	Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 2036-2045.	1.7	1
86	The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer. , 2022, 232, 108009.		3
87	De moleculaire biologie van urologische tumoren. , 2018, , 197-208.		0
92	Pan-cancer analysis of non-oncogene addiction to DNA repair. Scientific Reports, 2021, 11, 23264.	3.3	5
93	Nucleases and Co-Factors in DNA Replication Stress Responses. Dna, 2022, 2, 68-85.	1.3	4
94	A Novel DNA Damage Repair-Related Gene Signature for Predicting Glioma Prognosis. International Journal of General Medicine, 2021, Volume 14, 10083-10101.	1.8	3
96	A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. Molecular Cancer Therapeutics, 2022, 21, 786-798.	4.1	3

#	Article	IF	Citations
97	Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system. International Journal of Hematology, 2022, , .	1.6	0
98	Targeting mitochondrial DNA polymerase gamma for selective inhibition of MLH1 deficient colon cancer growth. PLoS ONE, 2022, 17, e0268391.	2.5	3
99	Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia. International Journal of Molecular Sciences, 2022, 23, 7051.	4.1	3
100	Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy. Molecules, 2022, 27, 4736.	3.8	10
101	Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer. International Journal of Molecular Sciences, 2022, 23, 10503.	4.1	4
102	BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. Cancers, 2022, 14, 5619.	3.7	3
103	A rapid multiplex cell-free assay on biochip to evaluate functional aspects of double-strand break repair. Scientific Reports, 2022, 12, .	3.3	0
104	Defektif Homolog Rekombinasyon DNA Tamiri ve PARP Ä°nhibisyonu ArasÄ±ndaki Sentetik Letal EtkileÅŸim. Journal of the Institute of Science and Technology, 0, , 2459-2475.	0.9	0
105	The role of SWI/SNF chromatin remodelers in the repair of DNA double strand breaks and cancer therapy. Frontiers in Cell and Developmental Biology, 0, 10, .	3.7	0
106	Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. Frontiers in Oncology, 0, 12, .	2.8	5
107	Nanomedicines with high drug availability and drug sensitivity overcome hypoxia-associated drug resistance. Biomaterials, 2023, 294, 122023.	11.4	10
108	Identification of DNA repair gene signature and potential molecular subtypes in hepatocellular carcinoma. Frontiers in Oncology, 0, 13, .	2.8	0
109	In Silico design and characterization of RAD51 protein inhibitors targeting homologous recombination repair for cancer therapy. Genome Instability & Disease, 2023, 4, 289-302.	1.1	0
110	Exploiting TLK1 and Cisplatin Synergy for Synthetic Lethality in Androgen-Insensitive Prostate Cancer. Biomedicines, 2023, 11, 2987.	3.2	0
111	Hypoxia-triggered tumor specific glutamine inhibition for reversing cisplatin resistance of chemotherapy. Chemical Engineering Journal, 2024, 479, 147692.	12.7	0
112	Cellular Responses to Widespread DNA Replication Stress. International Journal of Molecular Sciences, 2023, 24, 16903.	4.1	3
113	PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic Landscape. Life, 2024, 14, 198.	2.4	0
114	Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors. EMBO Reports, 2024, 25, 1469-1489.	4.5	0